利奈唑胺和万古霉素对院内感染MRSA肺炎疗效的meta分析  

A meta-analysis on treatment efficacy of linezolid versus vancomycin for nosocomial pneumonia of methicillinresistant Staphylococcus aureus

作　　者：石远峰[1] 陈晓兵[1] 谢永鹏[1] 顾彩虹[1] 殷睿宏[1] 

机构地区：[1]江苏省连云港市第一人民医院重症医学科,222002

出　　处：《中华灾害救援医学》2015年第11期623-626,共4页Chinese Journal of Disaster Medicine

摘　　要：目的比较利奈唑胺与万古霉素对耐甲氧西林金黄色葡萄球菌(methicillin-resistant Staphylococcus aureus,MRSA)感染的治疗效果。方法计算机检索Pubmed数据库、Embase数据库、CENTRAL图书馆,采用Rev Man5.3进行meta分析。纳入比较利奈唑胺和万古霉素治疗MRSA肺炎感染疗效的随机对照试验。结果纳入研究5项,共636例患者。meta分析结果显示,利奈唑胺组的临床治愈率高于万古霉素对照组[相对风险度(relative risk,RR)=1.27,95%可信区间(confidence interval,CI)(1.09,1.49),P<0.05];细菌清除率也高于万古霉素组[RR=1.19,95%CI(1.00,1.42),P=0.05]。结论对院内感染的MRSA肺炎,利奈唑胺的治疗效果优于万古霉素。Objective To evaluate the treatment efficacy of linezolid versus vancomycin for nosocomial pneumonia of methicillinresistant Staphylococcus aureus （MRSA）. Methods A systematic review of randomized controlled trials with meta-analysis performed by searching databases of PubMed, EMBASE, and Cochrane Central Register of Controlled Trials （CENTRAL）. Randomized controlled trials comparing linezolid and vancomycin therapies in patients with MRSA pneumonia were eligible for inclusion. Results Five trials were analyzed, involving 636 MRSA pneumonia patients. Meta-analysis showed that compared with vancomycin, linezolid was found to be superior for clinical cure rate in nosocomial pneumonia patients with MRSA infection [relative risk （ RR ） =1.27, 95% confidence interval （ CI ） = （1.09,- 1.49）, P〈0.05] ; MRSA eradication rate of linezolid in nosocomial pneumonia MRSA patients was higher than vancomycin [RR=1.19, 95% CI= （1.00, -1.42）, P=0.05]. Conclusions Linezolid is more effective than vancomyein for treatment of patients with nosocomial pneumonia of MRSA.

关 键 词：利奈唑胺 万古霉素 耐甲氧西林金黄色葡萄球菌 肺炎 

分 类 号：R978.1[医药卫生—药品]